Alexander Kaitlin M, Butts Charles Caleb, Lee Yan-Leei Larry, Kutcher Matthew E, Polite Nathan, Haut Elliott R, Spain David, Berndtson Allison E, Costantini Todd W, Simmons Jon D
Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Pharmacy, UF Health Shands Hospital, Gainesville, Florida, USA.
Trauma Surg Acute Care Open. 2023 May 12;8(1):e001070. doi: 10.1136/tsaco-2022-001070. eCollection 2023.
Pharmacological venous thromboembolism (VTE) prophylaxis is recommended in the vast majority of trauma patients. The purpose of this study was to characterize current dosing practices and timing of initiation of pharmacological VTE chemoprophylaxis at trauma centers.
This was an international, cross-sectional survey of trauma providers. The survey was sponsored by the American Association for the Surgery of Trauma (AAST) and distributed to AAST members. The survey included 38 questions about practitioner demographics, experience, level and location of trauma center, and individual/site-specific practices regarding the dosing, selection, and timing of initiation of pharmacological VTE chemoprophylaxis in trauma patients.
One hundred eighteen trauma providers responded (estimated response rate 6.9%). Most respondents were at level 1 trauma centers (100/118; 84.7%) and had >10 years of experience (73/118; 61.9%). While multiple dosing regimens were used, the most common dose reported was enoxaparin 30 mg every 12 hours (80/118; 67.8%). The majority of respondents (88/118; 74.6%) indicated adjusting the dose in patients with obesity. Seventy-eight (66.1%) routinely use antifactor Xa levels to guide dosing. Respondents at academic institutions were more likely to use guideline-directed dosing (based on the Eastern Association of the Surgery of Trauma and the Western Trauma Association guidelines) of VTE chemoprophylaxis compared with those at non-academic centers (86.2% vs 62.5%; p=0.0158) and guideline-directed dosing was reported more often if the trauma team included a clinical pharmacist (88.2% vs 69.0%; p=0.0142). Wide variability in initial timing of VTE chemoprophylaxis after traumatic brain injury, solid organ injury, and spinal cord injuries was found.
A high degree of variability exists in prescribing and monitoring practices for the prevention of VTE in trauma patients. Clinical pharmacists may be helpful on trauma teams to optimize dosing and increase prescribing of guideline-concordant VTE chemoprophylaxis.
绝大多数创伤患者推荐进行药物性静脉血栓栓塞症(VTE)预防。本研究的目的是描述创伤中心当前药物性VTE化学预防的给药实践和起始时间。
这是一项针对创伤医疗人员的国际性横断面调查。该调查由美国创伤外科学会(AAST)发起并分发给AAST成员。调查包括38个问题,涉及从业者的人口统计学、经验、创伤中心的级别和位置,以及关于创伤患者药物性VTE化学预防的给药、选择和起始时间的个人/机构特定实践。
118名创伤医疗人员回复(估计回复率6.9%)。大多数受访者来自一级创伤中心(100/118;84.7%)且有超过10年的经验(73/118;61.9%)。虽然使用了多种给药方案,但报告的最常见剂量是依诺肝素每12小时30mg(80/118;67.8%)。大多数受访者(88/118;74.6%)表示在肥胖患者中调整剂量。78人(66.1%)常规使用抗Xa因子水平来指导给药。与非学术中心的受访者相比,学术机构的受访者更有可能使用VTE化学预防的指南指导给药(基于东部创伤外科学会和西部创伤协会指南)(86.2%对62.5%;p = 0.0158),并且如果创伤团队中有临床药师,报告使用指南指导给药的频率更高(88.2%对69.0%;p = 0.0142)。发现创伤性脑损伤、实体器官损伤和脊髓损伤后VTE化学预防的初始时间存在很大差异。
创伤患者预防VTE的处方和监测实践存在高度差异。临床药师可能有助于创伤团队优化给药并增加符合指南的VTE化学预防的处方。